Home > Healthcare > Medical Devices > Therapeutic Devices > Photopheresis Products Market

Photopheresis Products Market Size

Report ID: GMI5958
Published Date: Jun 2023
Report Format: PDF

Download Free Sample

Photopheresis Products Market Size

Photopheresis Products Market size was valued at over USD 270 million in 2022 and is projected to reach more than USD 440 million by 2032 due to growing incidence of cutaneous T-cell lymphoma.

To get key market trends

Download Free Sample

Photopheresis products are used in a medical procedure known as extracorporeal photopheresis (ECP). This procedure involves the collection of a patient's blood, separation of specific components, treatment of those components with a photosensitizing agent, exposure of the treated components to ultraviolet (UV) light, and reinfusion of the treated blood components back into the patient. Photopheresis is primarily used for the treatment of certain blood disorders and immune-mediated conditions which are determined through performing various blood tests and other related tests.. For instance, multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system. It is estimated that there are approximately 2.8 million people suffering from with MS globally.

Photopheresis Products Market Report Attributes
Report Attribute	Details
Base Year:	2022
Photopheresis Products Market Size in 2022:	USD 277.2 Million
Forecast Period:	2023 to 2032
Forecast Period 2023 to 2032 CAGR:	5%
2032 Value Projection:	USD 448 Billion
Historical Data for:	2018 to 2022
No. of Pages:	200
Tables, Charts & Figures:	277
Segments covered:	Product Type, Application, End-use, and Region
Growth Drivers:	Rise in prevalence of autoimmune diseases Growing incidence of cutaneous T-cell lymphoma Increased government reimbursement policies and growing private healthcare insurance Technological advancements in photopheresis products
Pitfalls & Challenges:	High cost involved in therapy Lack of photopheresis treatment centres

Learn more about the key segments shaping this market

Download Free Sample

Moreover, increasing incidence of cutaneous T-cell lymphoma (CTCL) which is a rare form of non-Hodgkin lymphoma that predominantly impacts the skin. It is characterized by the abnormal proliferation of T lymphocytes in the skin. For instance, according to the Surveillance, Epidemiology, and End Results (SEER) data, the age-adjusted incidence rate of CTCL in the U.S. is estimated to be around 6.4 cases per million individuals per year.

Authors: Mariam Faizullabhoy

Frequently Asked Questions (FAQ) :

The global market for photopheresis products was valued at over USD 270 million in 2022 and is projected to reach more than USD 440 million by 2032. The growing prevalence of autoimmune diseases is accelerating market growth as these products are primarily used for the treatment of certain blood disorders and immune-mediated conditions.

The closed system segment held a notable revenue share of over USD 150 million in 2022 and will reach more than USD 240 million by 2032, as these closed systems are designed to minimize the risk of contamination during the photopheresis procedure.

The U.S. region accounted for more than USD 95 million in 2022 and will be worth over USD 150 million by 2032, backed by the affordability of photopheresis products among the target population base and ongoing technological developments.

Haemonetics Corporation, Fresenius Kabi, Terumo Corporation, Macopharma, Mallinckrodt Pharmaceuticals, Med Tech Solutions GmbH, Thermo Fisher Scientific, Spectranetics, Therakos, among others.